Panmure Gordon reaffirmed their buy rating on shares of ImmuPharma PLC (LON:IMM) in a research report report published on Friday morning. The brokerage currently has a GBX 100 ($1.31) price objective on the stock.

Several other analysts have also weighed in on IMM. Northland Securities reissued a corporate rating on shares of ImmuPharma PLC in a report on Wednesday, September 14th. Northland Capital Partners began coverage on ImmuPharma PLC in a report on Wednesday, July 20th. They issued a buy rating and a GBX 171 ($2.23) price objective for the company.

Shares of ImmuPharma PLC (LON:IMM) traded up 2.03% during trading on Friday, hitting GBX 37.75. The stock had a trading volume of 47,094 shares. ImmuPharma PLC has a one year low of GBX 19.10 and a one year high of GBX 48.88. The firm’s market cap is GBX 42.12 million. The firm’s 50-day moving average is GBX 37.27 and its 200-day moving average is GBX 33.54.

ImmuPharma PLC Company Profile

ImmuPharma plc (ImmuPharma) is a United Kingdom-based is a drug discovery and development company. Its research operations are in France. The Company is engaged in the development of drugs, primarily based on peptide therapeutics, to treat serious medical conditions, such as autoimmune diseases. ImmuPharma is engaged in developing drug candidates for five different medical conditions.

Receive News & Stock Ratings for ImmuPharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma PLC and related stocks with our FREE daily email newsletter.